Chronic PeriodontitisPhase 4NCT02641210
Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin
A Phase 4 study testing Periodontal Treatment and Albendazole in people with Chronic Periodontitis, run by Federal University of Maranhao.
Trial summary
Periodontitis is an inflammatory/infectious disease of high prevalence in the population and which has been linked to several chronic inflammatory systemic diseases. However, few studies have evaluated the periodontal disease in the absence of other inflammatory conditions stimulate inflammatory markers as C-reactive… Read more about this study
- Who is it for?
- Ages 30 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Periodontitis
- What is being tested?
- Periodontal Treatment and Albendazole
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- No sites listed yet
- Study dates
- Jan 2015to Oct 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Both sexes
- Aged 30-65 years
- Without other chronic systemic diseases except periodontitis
- At least 20 teeth
Who cannot join
- Diabetes mellitus
- Congestive heart failure
- Chronic kidney disease
- Malignant neoplasms
- Acquired immunodeficiency syndrome
- Hypertension
Show all 13Show fewer
- Pregnant women
- Nursing mothers
- Immunosuppressed by medication
- Women with changes in menstrual flow
- Smokers or ex-smokers for less than 10 years
- Usage history of NSAIDs or nonsteroidal and antibiotics within 3 months prior to the study and during the search
- Iron replacement in patients to treat anemia and carrying out subgingival scaling and periodontal surgery in 6 months prior to investigation.
About this study
Official title: Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin: a Clinical Trial
Periodontitis is an inflammatory/infectious disease of high prevalence in the population and which has been linked to several chronic inflammatory systemic diseases. However, few studies have evaluated the periodontal disease in the absence of other inflammatory conditions stimulate inflammatory markers as C-reactive protein (CRP), Interleukin - 6 (IL-6) hepcidin and hemoglobin. The aim of this study was to evaluate the influence of nonsurgical periodontal therapy on the change of inflammatory markers and anemia in control subjects and patients with chronic periodontitis after three months.This interventional study included 67 individuals of both sexes, aged 30-65 years, without other diseases, except chronic periodontitis, with at least 20 teeth, selected from a total 125 individuals following the eligibility criteria. Periodontal clinical parameters (probing depth, bleeding on probing, clinical attachment level) and systemic, hematological as well as inflammatory markers CRP, IL-6 and hepcidin were compared before and after nonsurgical periodontal therapy by serum and plasma examination of control individuals and patients with chronic periodontitis.
Read the detailed description
It conducted a non-randomized intervention study from April to October 2013, with individuals in the periodontics clinics of the Federal University of Maranhão State, São Luís, Brazil. The sample was selected from a total of 125 individuals, according to the eligibility criteria. Two groups were formed: experimental group (33 individuals) healthy patients except for the presence of chronic periodontitis in the advanced stage, and control group (30 subjects) patients without systemic disease proven by physical and biochemistry examination, and without chronic periodontitis.
The study was approved by the Ethics Committee on Human Research of the Federal University of Maranhão, São Luís, MA, Brazil under the protocol number 23115-010215 / 2011-16. All participants signed the consent form.
The sample size was defined on the basis of previous studies on the association between chronic periodontitis and systemic inflammatory markers.
All participants received an oral hygiene kit, attended a motivational speech with instructions on tooth brushing and flossing, and they were later referred for dental care.
At first visit, the medical record was checked for selecting volunteers without pre-diagnosed systemic diseases, in addition the general and periodontal clinical examination were performed, the urine collector was delivered, and drug intake [Albendazole 400 mg as a single dose]. After 15 days, subjects who met the initial selection criteria were sent for blood and urine collection for evaluation of biochemical markers. According to the results of laboratory tests, subjects were maintained or excluded after verification of those diagnosed with systemic diseases not previously identified.
The anamnesis and periodontal examination were carried out by a single trained examiner.It was collected the current and past medical and dental history, family history, social data, medications, possible changes of the menstrual flow, measurement of blood pressure, weight, height, and body mass index.
Oral clinical examination was also performed to diagnose the periodontal status of the participants. Then they were referred for dental care, according to their treatment needs.
After the therapy used, new clinical examination of the oral health of all participants was conducted 90 days after treatment. In the same period, new blood collection was performed for reassessment of biochemical markers.
The periodontal clinical examination used a periodontal probe type Williams in six sites per tooth (mesiobuccal, mid-buccal, it -vestibular, distolingual, medium-lingual, mesiolingual), performed by a single observer, dental surgeon, specialist in periodontics and previously trained. The intra-examiner concordance coefficient was 0.81 for probing depth and 0.77 for clinical attachment level. The following clinical parameters were evaluated: Probing depth (PD), gingival recession (GR), clinical attachment level (CAL), Visible Plaque Index (VPI), Bleeding on probing (BOP). This same examination at baseline was repeated 90 days after the initial examination and included the same clinical periodontal parameters.
Individuals who had at least two teeth with probing depth ≥ 5 mm and clinical attachment level ≥ 6 mm, associated with the presence of bleeding on probing, in the same site, 30 seconds after the first insertion probe, were diagnosed with periodontitis.
Blood samples (20ml) were collected in Ethylenediaminetetraacetic acid (EDTA) tubes after 12 hours fasting. The remainder of the EDTA-anticoagulated blood was centrifuged for 10 minutes at 3000 rpm to separate the plasma, aliquoted and stored at -70 until further analysis of the IL-6 concentrations.
The following laboratory tests were performed: total cholesterol, fasting glucose, triglycerides, albumin, glutamate oxalate transaminase, creatinine, uric acid, erythrocyte sedimentation rate (ESR), CRP, IL-6, Hepcidin, Serum Iron, Ferritin, Transferrin saturation, Blood parameters (hemoglobin, hematocrit, mean corpuscular volume - MCV, MCH), and urinalysis for abnormal elements and sediment (EAS).
Serum was obtained by addition of venous blood into a tube containing an activator of coagulation. After centrifugation for 15 minutes at 1800 rpm, the serum was separated. Serum was aliquoted piece for colorimetric evaluation of ferritin by chemiluminescence technique; serum iron and Ferrozine technique and transferrin saturation index, Goodwin's modified technique. The nephelometric was used for C-reactive protein of dosages and serum was stored at -70 °C remaining for analysis of hepcidin.
IL-6 and hepcidin were evaluated by the technique of immunoassay using ELISA kit, according to the manufacturer's instructions. Readings were made by automatic microplate reader and the absorbance was read at a wavelength of 450 nm in the spectrophotometer.
For statistical analysis, the investigators used a statistical software. Initially, there was a descriptive analysis through frequency measures, mean and standard deviation, median and interquartile range. Categorical variables were compared among groups using the chi-square test. The normal distribution of numerical variables was assessed Shapiro-Wilk test. The inferential analysis was made to assess the impact of the periodontal treatment on blood count variables, inflammatory markers, iron and periodontal parameters, used the paired Student's t test or the Wilcoxon test, and comparing the corresponding absolute delta between groups using the Mann-Whitney test. The significance level was set at 5%.
- Conditions
- Chronic Periodontitis
- Being tested
- Periodontal Treatment, Albendazole
- Keywords
- Chronic periodontitis, Hepcidin, Hemoglobin, Inflammation
- Medical subject headings
- Chronic Periodontitis, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Periodontal TreatmentProcedure or surgery
Also called Non-surgical Periodontal Therapy
Periodontal Treatment using Gracey curettes and ultrasonic device.
AlbendazoleDrug
Also called drug administration
All participants took Albendazole 400 mg before the intervention.
| Study group | Role | What they receive |
|---|---|---|
| Periodontal Treatment | Experimental | The experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration. Receives: Procedure: Periodontal Treatment; Drug: Albendazole |
| No Periodontal Treatment | No intervention | Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Hepcidin serum level after periodontal treatment as assessed by ELISA.
Measured: 90 days
Secondary outcomes (4)
Changes in periodontal outcomes (Probing depth in millimeters and clinical attachment level in millimeter) after periodontal treatment.
Measured: 90 days
Percentage of sites with visible plaque and /or bleeding on probing after periodontal treatment.
Measured: 90 days
Changes in us-CRP serum level after periodontal treatment as assessed by ELISA.
Measured: 90 days
Changes in Interleukin 6 serum level after periodontal treatment as assessed by ELISA.
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2015 (estimated)
- Study startJan 2015
- Primary completionJun 2015
- Study completionOct 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 63 participants (actual)
Sponsor and investigators
- Lead sponsor
- Federal University of Maranhao
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sandra Augusta de Moura Leite, Federal University of Maranhao
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02641210
- Sponsor's protocol ID
- 23115-010215/2011-16
- Status last verified
- Dec 2015
- First submitted
- 2 Oct 2015
- Last updated
- 29 Dec 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 29 Dec 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin: a Clinical Trial
- ClinicalTrials.gov ID
- NCT02641210
- Acronym / sponsor ID
- 23115-010215/2011-16
- Conditions
- Chronic Periodontitis
- Keywords
- Chronic periodontitis, Hepcidin, Hemoglobin, Inflammation
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 63 participants (actual)
- Lead sponsor
- Federal University of MaranhaoUniversity, hospital or other
- Study start
- Jan 2015
- Primary completion
- Jun 2015 (actual)
- Study completion
- Oct 2015 (actual)
- First posted
- 29 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Periodontitis is an inflammatory/infectious disease of high prevalence in the population and which has been linked to several chronic inflammatory systemic diseases. However, few studies have evaluated the periodontal disease in the absence of other inflammatory conditions stimulate inflammatory markers as C-reactive protein (CRP), Interleukin - 6 (IL-6) hepcidin and hemoglobin. The aim of this study was to evaluate the influence of nonsurgical periodontal therapy on the change of inflammatory markers and anemia in control subjects and patients with chronic periodontitis after three months.This interventional study included 67 individuals of both sexes, aged 30-65 years, without other diseases, except chronic periodontitis, with at least 20 teeth, selected from a total 125 individuals following the eligibility criteria. Periodontal clinical parameters (probing depth, bleeding on probing, clinical attachment level) and systemic, hematological as well as inflammatory markers CRP, IL-6 and hepcidin were compared before and after nonsurgical periodontal therapy by serum and plasma examination of control individuals and patients with chronic periodontitis.
Detailed description
It conducted a non-randomized intervention study from April to October 2013, with individuals in the periodontics clinics of the Federal University of Maranhão State, São Luís, Brazil. The sample was selected from a total of 125 individuals, according to the eligibility criteria. Two groups were formed: experimental group (33 individuals) healthy patients except for the presence of chronic periodontitis in the advanced stage, and control group (30 subjects) patients without systemic disease proven by physical and biochemistry examination, and without chronic periodontitis.
The study was approved by the Ethics Committee on Human Research of the Federal University of Maranhão, São Luís, MA, Brazil under the protocol number 23115-010215 / 2011-16. All participants signed the consent form.
The sample size was defined on the basis of previous studies on the association between chronic periodontitis and systemic inflammatory markers.
All participants received an oral hygiene kit, attended a motivational speech with instructions on tooth brushing and flossing, and they were later referred for dental care.
At first visit, the medical record was checked for selecting volunteers without pre-diagnosed systemic diseases, in addition the general and periodontal clinical examination were performed, the urine collector was delivered, and drug intake [Albendazole 400 mg as a single dose]. After 15 days, subjects who met the initial selection criteria were sent for blood and urine collection for evaluation of biochemical markers. According to the results of laboratory tests, subjects were maintained or excluded after verification of those diagnosed with systemic diseases not previously identified.
The anamnesis and periodontal examination were carried out by a single trained examiner.It was collected the current and past medical and dental history, family history, social data, medications, possible changes of the menstrual flow, measurement of blood pressure, weight, height, and body mass index.
Oral clinical examination was also performed to diagnose the periodontal status of the participants. Then they were referred for dental care, according to their treatment needs.
After the therapy used, new clinical examination of the oral health of all participants was conducted 90 days after treatment. In the same period, new blood collection was performed for reassessment of biochemical markers.
The periodontal clinical examination used a periodontal probe type Williams in six sites per tooth (mesiobuccal, mid-buccal, it -vestibular, distolingual, medium-lingual, mesiolingual), performed by a single observer, dental surgeon, specialist in periodontics and previously trained. The intra-examiner concordance coefficient was 0.81 for probing depth and 0.77 for clinical attachment level. The following clinical parameters were evaluated: Probing depth (PD), gingival recession (GR), clinical attachment level (CAL), Visible Plaque Index (VPI), Bleeding on probing (BOP). This same examination at baseline was repeated 90 days after the initial examination and included the same clinical periodontal parameters.
Individuals who had at least two teeth with probing depth ≥ 5 mm and clinical attachment level ≥ 6 mm, associated with the presence of bleeding on probing, in the same site, 30 seconds after the first insertion probe, were diagnosed with periodontitis.
Blood samples (20ml) were collected in Ethylenediaminetetraacetic acid (EDTA) tubes after 12 hours fasting. The remainder of the EDTA-anticoagulated blood was centrifuged for 10 minutes at 3000 rpm to separate the plasma, aliquoted and stored at -70 until further analysis of the IL-6 concentrations.
The following laboratory tests were performed: total cholesterol, fasting glucose, triglycerides, albumin, glutamate oxalate transaminase, creatinine, uric acid, erythrocyte sedimentation rate (ESR), CRP, IL-6, Hepcidin, Serum Iron, Ferritin, Transferrin saturation, Blood parameters (hemoglobin, hematocrit, mean corpuscular volume - MCV, MCH), and urinalysis for abnormal elements and sediment (EAS).
Serum was obtained by addition of venous blood into a tube containing an activator of coagulation. After centrifugation for 15 minutes at 1800 rpm, the serum was separated. Serum was aliquoted piece for colorimetric evaluation of ferritin by chemiluminescence technique; serum iron and Ferrozine technique and transferrin saturation index, Goodwin's modified technique. The nephelometric was used for C-reactive protein of dosages and serum was stored at -70 °C remaining for analysis of hepcidin.
IL-6 and hepcidin were evaluated by the technique of immunoassay using ELISA kit, according to the manufacturer's instructions. Readings were made by automatic microplate reader and the absorbance was read at a wavelength of 450 nm in the spectrophotometer.
For statistical analysis, the investigators used a statistical software. Initially, there was a descriptive analysis through frequency measures, mean and standard deviation, median and interquartile range. Categorical variables were compared among groups using the chi-square test. The normal distribution of numerical variables was assessed Shapiro-Wilk test. The inferential analysis was made to assess the impact of the periodontal treatment on blood count variables, inflammatory markers, iron and periodontal parameters, used the paired Student's t test or the Wilcoxon test, and comparing the corresponding absolute delta between groups using the Mann-Whitney test. The significance level was set at 5%.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Periodontal Treatment | Experimental | Procedure: Periodontal Treatment, Drug: AlbendazoleThe experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration. |
| No Periodontal Treatment | No intervention | –Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline. |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Both sexes
- Aged 30-65 years
- Without other chronic systemic diseases except periodontitis
- At least 20 teeth
Key exclusion criteria (13 listed)
- Diabetes mellitus
- Congestive heart failure
- Chronic kidney disease
- Malignant neoplasms
- Acquired immunodeficiency syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Periodontal TreatmentAlso: Non-surgical Periodontal TherapyPeriodontal Treatment using Gracey curettes and ultrasonic device. | Procedure or surgery | Periodontal Treatment |
| AlbendazoleAlso: drug administrationAll participants took Albendazole 400 mg before the intervention. | Drug | Periodontal Treatment |
Primary outcome
Changes in Hepcidin serum level after periodontal treatment as assessed by ELISA.
Time frame: 90 days
4 secondary outcomes
Changes in periodontal outcomes (Probing depth in millimeters and clinical attachment level in millimeter) after periodontal treatment.
Time frame: 90 days
Percentage of sites with visible plaque and /or bleeding on probing after periodontal treatment.
Time frame: 90 days
Changes in us-CRP serum level after periodontal treatment as assessed by ELISA.
Time frame: 90 days
Changes in Interleukin 6 serum level after periodontal treatment as assessed by ELISA.
Time frame: 90 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Dec 2015.
Related trials for Chronic Periodontitis
Not yet recruiting
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
Chronic Apical Periodontitis, Pulp Necrosis
Recruiting
Effect of Cyperus Articulatus on Bacterial Reduction and Postoperative Pain
Chronic Apical Periodontitis
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingObservational study
Evaluation of Masticatory Performance in Patients With Periodontitis
Periodontitis, Adult, Periodontitis
Recruiting
Postoperative Pain and Success of Single-Visit Root Canal Treatment Using Different Root Canal Sealers in Asymptomatic Teeth
Single-visit, Periapical Periodontitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Periodontal Treatment and Albendazole in people with Chronic Periodontitis, run by Federal University of Maranhao.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Hepcidin serum level after periodontal treatment as assessed by ELISA. (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2015.